Infectious complications of chimeric antigen receptor T cell therapy and bispecific antibodies - A review
Bradley Dye1, Daniel Gromer2, Bibi Maryam1
1Infectious Diseases Section, Department of Medicine, College of Medicine, University of Oklahoma, Oklahoma City, OK, USA.
The American Journal of the Medical Sciences
|October 20, 2025
Abstract:
Chimeric antigen receptor (CAR) T cell therapy has shifted the therapeutic landscape of hematological malignancies in the last decade, and bispecific antibodies (BsAb) are an emerging treatment for this patient population. Immunosuppression associated with these therapies can lead to a variety of infectious complications. In this narrative review, we explore the epidemiology, risk factors and prevention of bacterial, viral and fungal infections after CAR T cell and BsAb therapy.


